Our study demonstrates that some hyperimmune COVID-IVIG lots manufactured in 2020 (2020-hCoV-2IG) neutralized several Omicron variants, similar to CP, from Omicron breakthrough infections in individuals with prior vaccination (2022-CP), at a level (PsVNA50 titer of >1:40) predicted to provide protection against severe COVID-19 (4). The gene discussed is CP; the disease is COVID-19.